ArticleDermatology (Basel, Switzerland)2022

Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.

Katharina A Drerup et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.